Company news
Tempus Ai, Inc. (NASDAQ:TEM) news
Tempus Ai, Inc. news releases on 6ix. Latest, May 6, 2025: Tempus Reports First Quarter 2025 Results
Press releases — page 3
Tempus Reports First Quarter 2025 Results
May 5, 2025
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
May 4, 2025
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
April 30, 2025
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
April 28, 2025
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
April 27, 2025
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
April 24, 2025
Tempus to Report First Quarter 2025 Financial Results on May 6
April 23, 2025
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
April 22, 2025
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
April 17, 2025
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
April 14, 2025
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
March 28, 2025
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
March 25, 2025
Tempus Announces Acquisition of Deep 6 AI
March 10, 2025
Tempus Reports Fourth Quarter and Full Year 2024 Results
February 23, 2025
Tempus to Present at TD Cowen's 45th Annual Health Care Conference
February 18, 2025
Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
February 17, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million
February 17, 2025
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
February 12, 2025
Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24
February 10, 2025
Tempus Completes Acquisition of Ambry Genetics
February 2, 2025
Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
January 20, 2025
Tempus Announces the National Launch of FDA-Approved xT CDx Test
January 14, 2025
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
January 13, 2025
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
January 12, 2025
Tempus Announces Its First-Ever, Whole-Genome Sequencing Assay, xH
January 12, 2025
Tempus Announces a Collaboration With Genialis to Develop RNA-Based Biomarker Algorithms
January 7, 2025
Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
December 17, 2024
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
December 16, 2024
Personalis and Tempus Expand Collaboration to Biopharma
December 15, 2024
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 24, 2024
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
November 11, 2024
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
November 10, 2024
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
November 7, 2024
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
November 6, 2024
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
November 3, 2024
Tempus to Report Third Quarter 2024 Financial Results on November 4
November 2, 2024
Tempus to Report Third Quarter 2024 Financial Results on November 7
October 23, 2024
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
September 25, 2024
Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024
September 12, 2024
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
September 11, 2024
Tempus Announces Real World Data Collaboration with BioNTech
September 3, 2024
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 27, 2024
Personalis and Tempus Announce Expanded Collaboration
August 15, 2024
NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay
August 7, 2024
Tempus Reports Second Quarter 2024 Results
August 5, 2024
Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2
July 31, 2024
Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics
July 29, 2024
GeneCentric Therapeutics Announces American Medical Association Has Granted a PLA Code for PurIST Pancreatic Cancer Test
July 23, 2024
Tempus to Report Second Quarter 2024 Financial Results on August 6
July 16, 2024